NTG Nordic Transport Group A/S – Q3 2025 Conference Call
October 10, 2025 04:00 ET | Source: NTG Nordic Transport Group A/S…
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinsons disease
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Kia Announces September 2025 Global Sales Results
September 2025 global sales of 268,238 units, up 7.3% Y/ySales in Korea…
Omdia Forecasts Large-Area Display Shipments to Grow 2.8% YoY in 2025, Mobile PC Displays Lead the Growth
LONDON--(BUSINESS WIRE)--#Consumer--According to the latest analysis from Omdia’s Large-area display market tracker…
Euro NCAP to Launch New SAFER TRUCKS Results
WhatLatest Euro NCAP truck safety results published online and via social media.WhenTuesday 30…
Silynxcom Announces First Half of 2025 Financial Results, Expands Client Diversity and Raised $2.9M to Support Growth
September 26, 2025 16:05 ET | Source: Silynxcom Ltd. Netanya, Israel, Sept.…
Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025
September 26, 2025 16:04 ET | Source: Maris-Tech Ltd. The company continues…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…